Allen v. Koenigsmann

Background

Peter Allen is an inmate housed at Eastern Correctional Facility, a prison supervised by the New York State Department of Corrections and Community Supervision. The opinion describes Allen as suffering from chronic pain, neuropathy, arthritis, spinal conditions, and other medical problems. Dr. Ann Andola treated him as a primary-care physician. Dr. Susan Mueller and Dr. David Dinello were regional medical directors, and Dr. Mikhail Gusman periodically treated Allen.

In 2017, the department adopted a Medications With Abuse Potential policy. The policy required medical providers to obtain approval from a regional medical director before prescribing certain medications for long-term treatment, including Neurontin and Lyrica. Dr. Andola requested approval to continue Allen’s Neurontin prescription in June 2017. Mueller and Dinello denied the request and directed Andola toward alternative treatments. Allen was then weaned off Neurontin. In October 2018, Andola requested approval for a trial of Lyrica, but Mueller denied that request as well. Dinello was not involved in the Lyrica decision.

Allen brought two claims under 42 U.S.C. § 1983, a federal law allowing claims against government officials for constitutional violations. He alleged that the defendants were deliberately indifferent to his serious medical needs in violation of the Eighth Amendment. The defendants moved for summary judgment, which asks whether the evidence presents a genuine factual dispute requiring a trial. A prior related class action had sought damages and injunctive relief concerning the policy; after the court declined to certify a damages class, Allen filed this individual damages case. The opinion also states that Carl Koenigsmann was dismissed from this case with prejudice before the ruling.

Legal standards

For an Eighth Amendment medical-care claim, Allen had to show both that the challenged deprivation was sufficiently serious and that each defendant knowingly disregarded an excessive risk to his health. Because the claims were brought under Section 1983, Allen also had to show each defendant’s personal involvement through that defendant’s own actions or omissions.

The court also considered qualified immunity, which can protect government officials from damages when their conduct did not violate a clearly established constitutional right or was objectively reasonable under the circumstances. At the summary-judgment stage, the court had to view disputed evidence and reasonable inferences in Allen’s favor.

Neurontin denial

The court held that the evidence satisfied the serious-deprivation requirement for the Neurontin claim. Allen had documented chronic and substantial pain, and the record indicated that Neurontin had improved his symptoms. The court concluded that replacing or withholding Neurontin created a particular risk that Allen would suffer aggravated and unnecessary chronic pain, even though alternative treatments were provided.

The court denied summary judgment for Mueller and Dinello on the Neurontin decision. Their evidence showed that they considered the risks of addiction, abuse, and diversion and favored safer alternatives. But the court found that the evidence did not establish, as a matter of law, that they adequately considered the effectiveness of Allen’s prior Neurontin treatment or the risk that his pain would worsen without it. A reasonable jury could therefore find that they knowingly disregarded an excessive risk to Allen’s health.

The court also rejected qualified immunity for Mueller and Dinello on this issue. It held that precedent clearly established an inmate’s right not to have officials reflexively apply a policy to deny a medication when they knew the medication might be medically appropriate and the treating physician recommended it.

Lyrica denial

The court reached a different conclusion regarding Mueller’s denial of the October 2018 Lyrica request. Unlike the evidence concerning Neurontin, Mueller’s evidence showed that she considered Allen’s treatment history, the limited or outdated physical therapy, the lack of identified specialist referrals, possible alternative medications, and the risks associated with Lyrica. The court concluded that the record did not support a finding that Mueller consciously disregarded the risk that denying Lyrica would cause Allen unnecessary additional pain.

The State Represented Defendants’ motion was therefore granted with respect to the Lyrica request. The court did not need to decide their separate argument that Allen failed to exhaust administrative remedies after the Lyrica denial.

Andola and Gusman

The court denied the motion by Andola and Gusman in its entirety. As to Andola, the court found factual disputes about whether she knew of effective ways to seek approval after the medication requests were denied, whether she pursued those options, and whether she consciously chose less effective treatment. Those disputes prevented summary judgment on both deliberate indifference and qualified immunity.

As to Gusman, the court acknowledged that merely being copied on emails about the Neurontin request would not establish personal involvement. But Allen testified that, after Neurontin was discontinued, he told Gusman about his pain and said the replacement medications were not treating it effectively. Although that testimony was vague about when the conversation occurred and what Allen expected Gusman to do, the court held that it created factual disputes about Gusman’s knowledge, personal involvement, response, and possible disregard of the risk of continued unnecessary pain. Those disputes also prevented summary judgment based on qualified immunity.

Disposition

The State Represented Defendants’ motion was granted in part and denied in part: it was denied as to the June 9, 2017 Neurontin request and granted as to the October 4, 2018 Lyrica request. The Non-State Represented Defendants’ motion was denied in its entirety. The court scheduled trial for October 28, 2024.